Making Safer and More Effective Vaccines with Targeted mRNA

Thomas VanCott, chief scientific officer of Combined Therapeutics, discusses the company’s mRNA platform for vaccines, the advantages it provides, and its potential to use the same approach to train the immune system on specific mutations in a tumor.